Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration of PC945, its novel inhaled triazole, with systemic standard oral treatments against Aspergillus fumigatus (AF) in vitro and in a preclinical mouse model in the prestigious peer reviewed publication Scientific Reports (Nature Research) [ Scientific Reports, volume 9, Article number: 9482 (2019)]. https://www.nature.com/articles/s41598-019-45890-w
